



ASX Announcement

1 March, 2017

## **Creso Pharma expands its Scientific Advisory Board and strengthens Swiss presence with appointment of Prof. Dr. med Felix Gutzwiller**

### **Highlights:**

- **Creso Pharma is honoured to appoint Prof. Dr. med Felix Gutzwiller to its Scientific Advisory Board.**
- **Prof. Dr. med Gutzwiller brings more than 30 years' experience across medicine, public health and politics.**
- **Appointment enhances Creso's scientific, medical and public health capabilities for the development and marketing of its products towards more optimal patient outcomes and efficiency in healthcare.**
- **Strengthens Creso's presence in Switzerland.**

**Creso Pharma Limited** (ASX:CPH, the "Company") is delighted to welcome Prof. Dr. med Felix Gutzwiller as a new member of its Scientific Advisory Board.

The appointment strengthens Creso's scientific, medical and government relations capabilities for the development and marketing of its innovative therapeutics and strengthens the Company's presence in the Swiss market, with Prof. Dr. med Gutzwiller bringing more than 30 years' experience across medicine, public health and politics.

He joins Dr. Isaac Kobrin (ex Actelion Chief Medical Officer), Switzerland, Dr. Raquel Peyraube, Uruguay, and Dr. Stephane Redey, (ex Actelion) Australia, on the Scientific Advisory Board.

Prof. Dr. med Gutzwiller holds the titles of MD of the University of Basel, Master in Public Health of the Harvard School of Public Health and Doctor of Public Health of the Johns Hopkins University School of Hygiene and Public Health.

As well as being a member of several public health boards, Prof. Dr. med Gutzwiller has presided over several Health Research Councils, Health and Social Prevention Societies, the Swiss Society for Health Policy, the Board of Governors of the Swiss Tropical and Public Health Institute and was Founding President of the Swiss School of Public Health.

He was Professor at the University of Lausanne and Professor of Social and Preventive Medicine at the University of Zürich from 1988 to 2013, and has been an Emeritus Professor at the University of Zurich since 2013.



Prof. Dr. med Felix Gutzwiller has also had a successful political career spanning 16 years. He was an elected member of the Swiss Parliament (National Council and Council of States), and has shown strong engagement and leadership in the development and implementation of innovative and sound healthcare policies in Switzerland and internationally.

“We are very honoured and grateful to have Felix as a new member of our Scientific Advisory Board. His outstanding personal qualities and his scientific, medical and political experience will further energise and enhance our capabilities towards optimising patients’ health outcomes on the road towards improved efficiency in healthcare. We warmly welcome Felix to Creso’s Scientific Advisory Board,” said Creso Pharma Group CEO and Co-Founder, Dr Miriam Halperin Wernli.

---END---

**Investor Enquiries:**

Gabriella Hold  
M: 0411 364 382  
E: [gabriella.hold@mcpartners.com.au](mailto:gabriella.hold@mcpartners.com.au)

**Media Enquiries:**

Harrison Polites  
M: 0409 623 618  
E: [harrison.polites@mcpartners.com.au](mailto:harrison.polites@mcpartners.com.au)

**Corporate Queries:**

EverBlu Capital  
Level 39, Aurora Place  
88 Phillip Street, Sydney, NSW 2000  
E: [info@everblucapital.com](mailto:info@everblucapital.com)  
P: +61 2 8249 4371

**About Creso Pharma**

Creso Pharma brings pharmaceutical expertise and methodological rigour to the world of medical cannabis and strives for the highest quality in its products. It is the leader in cannabidiol (CBD) innovation and develops cannabis- and hemp-derived therapeutic-grade CBD nutraceuticals and medical cannabis products with wide patient reach for human and animal health. Creso uses GMP development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids. The Company is already generating revenues via its subsidiary, Hemp-Industries.